Group 1 - The report emphasizes the importance of cultivating patient capital to support the development of new productive forces, aligning with national strategies for technological self-reliance and innovation [1][23][27] - Patient capital matches the investment cycle of new productive forces, effectively helping innovative companies overcome critical development phases [1][25][27] - The investment philosophy of patient capital aligns with the disruptive innovation characteristics of new productive forces, providing continuous funding for technological advancements [1][26][27] Group 2 - The report highlights the rapid growth of patient capital in China, with various types of capital actively participating in supporting technology-driven enterprises [3][19] - The semiconductor and electronic equipment sectors are leading in investment heat, with significant growth in hard technology fields [3][19] - The report identifies that the characteristics of rapidly advancing companies in smart manufacturing and AI include strong R&D capabilities, high market influence, and significant growth potential [4][19] Group 3 - The report outlines that patient capital is primarily sourced from government-guided funds, sovereign wealth funds, private equity, and venture capital in China [19][22] - It notes that patient capital can manifest in various forms, including venture capital for startups and private equity for growth-stage companies [28][29] - The report discusses the role of long-term funds such as pensions and insurance in providing patient capital, emphasizing their focus on stable, long-term investments [33][34]